Athira Pharma (NASDAQ:LONA) Releases Quarterly Earnings Results

Athira Pharma (NASDAQ:LONA) announced its quarterly earnings results on Thursday. The company reported ($18.90) earnings per share (EPS) for the quarter, FiscalAI reports.

Athira Pharma Stock Down 5.2%

Shares of NASDAQ LONA traded down $0.51 during midday trading on Friday, hitting $9.17. 14,098 shares of the company’s stock traded hands, compared to its average volume of 77,765. The firm has a market capitalization of $36.15 million, a P/E ratio of -0.95 and a beta of 2.68. Athira Pharma has a 1 year low of $2.20 and a 1 year high of $14.21.

Insider Activity

In related news, CEO Mark James Litton sold 5,156 shares of Athira Pharma stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $5.37, for a total transaction of $27,687.72. Following the transaction, the chief executive officer directly owned 57,926 shares in the company, valued at approximately $311,062.62. The trade was a 8.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have sold 9,110 shares of company stock worth $48,921. Insiders own 25.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on LONA. Weiss Ratings assumed coverage on shares of Athira Pharma in a report on Wednesday, February 11th. They issued a “sell (d-)” rating for the company. Cantor Fitzgerald began coverage on shares of Athira Pharma in a research report on Thursday, February 26th. They set an “overweight” rating for the company. Mizuho upgraded shares of Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 price objective for the company in a report on Thursday, February 19th. Wall Street Zen cut Athira Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Zacks Research upgraded Athira Pharma to a “hold” rating in a research note on Friday, February 27th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Athira Pharma Company Profile

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.